TCI Wealth Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

TCI Wealth Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.7K	Hold	11,000	–	–	﹤0.01%	262
2026 Q1	$79.6K	Hold	11,000	–	–	﹤0.01%	247
2025 Q4	$83K	Hold	11,000	–	–	﹤0.01%	250
2025 Q3	$64.9K	Buy	+11,000	New	+$59.9K	﹤0.01%	261

Other funds holding EPRX

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

TCI Wealth Advisors's EPRX Position: Q2 2026 in Review

TCI Wealth Advisors held its Eupraxia Pharmaceuticals (EPRX) position steady in Q2 2026 at 11,000 shares worth $72.7K. The position accounts for ﹤0.01% of the portfolio, ranked #262.

TCI Wealth Advisors first reported a position in EPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $83K in Q4 2025. 3 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

TCI Wealth Advisors held 11,000 shares of Eupraxia Pharmaceuticals worth $72.7K as of Q2 2026.
TCI Wealth Advisors left its Eupraxia Pharmaceuticals share count unchanged in Q2 2026.
Eupraxia Pharmaceuticals made up ﹤0.01% of TCI Wealth Advisors's portfolio in Q2 2026, its #262 holding.
TCI Wealth Advisors first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
TCI Wealth Advisors's Eupraxia Pharmaceuticals position peaked at $83K in Q4 2025.
3 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on TCI Wealth Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.